Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy.

摘要: // Ismael Riquelme 1,* , Kathleen Saavedra Jaime A. Espinoza 2,3 Helga Weber 1 Patricia Garcia Bruno Nervi 3,4,5 Marcelo Garrido 3,4 Alejandro H. Corvalan 3,4,6 Juan Carlos Roa 2,3,6 and Carolina Bizama Department of Pathology, School Medicine, Universidad de La Frontera, CEGIN-BIOREN, Temuco, Chile 2 Pontificia Catolica Chile, Santiago, 3 UC-Center for Investigational Oncology (CITO), 4 Hematology Oncology, 5 Millennium Institute on Immunology Immunotherapy, 6 Advanced Center Chronic Diseases (ACCDIS), * These authors contributed equally to this work Correspondence to: Bizama, email: Roa, Keywords : gastric cancer, chemotherapy, molecular classification, signaling pathway, cancer stem cells Received April 16, 2015 Accepted July 17, Published 22, Abstract Gastric (GC) is the third leading cause mortality worldwide. Although surgical resection a potentially curative approach localized cases GC, most GC are diagnosed in an advanced, non-curable stage response traditional chemotherapy limited. Fortunately, recent advances our understanding mechanisms that mediate hold great promise development more effective treatment strategies. In review, overview morphological current approaches, alterations have been characterized provided. particular, classification identified relevant pathways, including ErbB, VEGF, PI3K/AKT/mTOR, HGF/ MET described, as well inhibitors these pathways. An completed active clinical trials related pathways also summarized. Finally, insights regarding emerging cell may provide additional novel markers therapeutic agents against GC. The identification biomarkers can be used diagnosis, prognosis, individualized therapy patients, potential improve efficacy, safety, cost-effectiveness treatments.